New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma
Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma FUTURE ONCOLOGY Seetharam, M., Kolla, K. R., Ganjoo, K. N. 2018; 14 (23): 2323–33Abstract
Soft tissue sarcomas are a group of rare tumors of mesenchymal origin, and account for less than 1% of all cancers. The most commonly used drug for the treatment of soft tissue sarcoma is anthracycline chemotherapeutic agent, doxorubicin. The major limitation for doxorubicin is cardiotoxicity. Hence, to overcome this limitation and to increase efficacy, aldoxorubicin was developed, which has demonstrated activity in soft tissue sarcomas without much cardiotoxicity. In this review article, we discuss mechanism of action, pharmacokinetics, preclinical studies, clinical trial data and safety profile of aldoxorubicin and its potential applicability in the future of sarcoma treatment.
View details for DOI 10.2217/fon-2018-0047
View details for Web of Science ID 000449031200002
View details for PubMedID 29869517